LPCN Lipocine Inc.

0.4
-0.01  -3%
Previous Close 0.41
Open 0.41
Price To Book 1.9
Market Cap 14,319,275
Shares 35,851,965
Volume 683,168
Short Ratio
Av. Daily Volume 636,676
Stock charts supplied by TradingView

NewsSee all news

  1. Lipocine Announces Closing Of Public Offering Of Common Stock And Warrants

    SALT LAKE CITY, Nov. 18, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the closing of a public offering of (i)

  2. Lipocine Announces Pricing Of Public Offering Of Common Stock And Warrants

    SALT LAKE CITY, Nov. 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the pricing of a public

  3. Lipocine Announces Launch Of Public Offering Of Common Stock And Warrants

    SALT LAKE CITY, Nov. 13, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the launch of a public offering of units

  4. Lipocine Announces Third Quarter 2019 Financial and Operational Results

    SALT LAKE CITY, Nov. 12, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter and nine months ended September 30, 2019, and

  5. Lipocine Receives Complete Response Letter for TLANDO™ from U.S. FDA

    SALT LAKE CITY, Nov. 11, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company, announced today that it has received a Complete Response Letter ("CRL") from the United

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b top-line data released September 2016. Seeking feedback from FDA regarding Phase 3 design.
LPCN 1111
Oral testosterone product
CRL announced November 11, 2019.
TLANDO - LPCN 1021
Men with low testosterone (Low T)
Conduct food/fact effect study in preparation for Phase 3 trial.
LPCN 1107
Prevention of preterm birth ("PTB").
Phase 2 data due mid-2020.
LPCN 1144
Non-alcoholic fatty liver disease (NAFLD) / Non-alcoholic steatohepatitis (NASH)

Latest News

  1. Lipocine Announces Closing Of Public Offering Of Common Stock And Warrants

    SALT LAKE CITY, Nov. 18, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the closing of a public offering of (i)

  2. Lipocine Announces Pricing Of Public Offering Of Common Stock And Warrants

    SALT LAKE CITY, Nov. 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the pricing of a public

  3. Lipocine Announces Launch Of Public Offering Of Common Stock And Warrants

    SALT LAKE CITY, Nov. 13, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the launch of a public offering of units

  4. Lipocine Announces Third Quarter 2019 Financial and Operational Results

    SALT LAKE CITY, Nov. 12, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter and nine months ended September 30, 2019, and

  5. Lipocine Receives Complete Response Letter for TLANDO™ from U.S. FDA

    SALT LAKE CITY, Nov. 11, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company, announced today that it has received a Complete Response Letter ("CRL") from the United

  6. Lipocine to Present at the B. Riley NASH Symposium

    SALT LAKE CITY, Oct. 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), clinical-stage biopharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will participate in a panel

  7. Lipocine to Present at the H.C. Wainwright 3rd Annual NASH Investor Conference

    SALT LAKE CITY, Oct. 10, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), clinical-stage biopharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview

  8. Lipocine To Present LPCN 1144 Poster Of Distinction At The Liver Meeting® 2019

    SALT LAKE CITY, Oct. 1, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that data from a clinical trial of LPCN

  9. First Biopsy Confirmed Nash Patient Dosed In Lipocine LiFT Study Of LPCN 1144

    SALT LAKE CITY, Sept. 30, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the first patient has been dosed

  10. Lipocine Announces Presentations at the 20th Annual Fall Meeting of the Sexual Medicine Society of North America

    SALT LAKE CITY, Sept. 23, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that four abstracts (two oral

  11. Lipocine to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    SALT LAKE CITY, Sept. 17, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that Dr. Mahesh Patel, Chairman,

  12. Lipocine to Participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma, Rare Disease & Gene Therapy

    SALT LAKE CITY, Sept. 16, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that Dr. Mahesh Patel, Chairman,

  13. Lipocine Announces Trial Date in Lipocine's Infringement Lawsuit Against Clarus Therapeutics and Will Seek a Permanent Injunction

    SALT LAKE CITY, Aug. 27, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that the U.S. District Court of Delaware